S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Bear market expert makes new prediction (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Bear market expert makes new prediction (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
Bear market expert makes new prediction (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NASDAQ:ARVN

Arvinas - ARVN Stock Forecast, Price & News

$27.32
+0.51 (+1.90%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$26.51
$27.79
50-Day Range
$26.15
$37.26
52-Week Range
$25.35
$75.39
Volume
554,490 shs
Average Volume
502,610 shs
Market Capitalization
$1.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.75

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.72 Rating Score
Upside/​Downside
151.6% Upside
$68.75 Price Target
Short Interest
Bearish
11.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$256,143 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.01) to ($7.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

616th out of 1,004 stocks

Pharmaceutical Preparations Industry

301st out of 489 stocks


ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

Analysts Set Arvinas, Inc. (NASDAQ:ARVN) PT at $68.44
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)
Arvinas to Participate in Upcoming Investor Conferences
Where Are The Markets Going Next?
More banking collapses could be imminent. If you have any money (at all) invested in the markets... even just your retirement... you'll want to see THIS. What we reveal now could help you sooner (and you won’t want it to be later). pixel
Arvinas to Present at Upcoming Conferences
Why Arvinas (ARVN) Might Surprise This Earnings Season
Arvinas Gives Back to Local Greater New Haven Community
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings
2/23/2023
Today
3/31/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$68.75
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+151.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.72
Research Coverage
18 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-228.19%
Pretax Margin
-191.02%

Debt

Sales & Book Value

Annual Sales
$131.40 million
Book Value
$10.61 per share

Miscellaneous

Free Float
51,790,000
Market Cap
$1.46 billion
Optionable
Not Optionable
Beta
1.78

Key Executives

  • John G. HoustonJohn G. Houston
    President, Chief Executive Officer & Director
  • Lisa Sinclair
    Senior Vice President-Corporate Operations
  • Sean A. CassidySean A. Cassidy
    Chief Financial Officer
  • Ian TaylorIan Taylor
    Chief Scientific Officer
  • Ronald PeckRonald Peck
    Chief Medical Officer













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2023?

18 Wall Street research analysts have issued twelve-month target prices for Arvinas' shares. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they anticipate the company's stock price to reach $68.75 in the next year. This suggests a possible upside of 151.6% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2023?

Arvinas' stock was trading at $34.21 on January 1st, 2023. Since then, ARVN stock has decreased by 20.1% and is now trading at $27.32.
View the best growth stocks for 2023 here
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) announced its quarterly earnings results on Thursday, February, 23rd. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.10) by $0.46. The company earned $38 million during the quarter, compared to the consensus estimate of $35.32 million. Arvinas had a negative trailing twelve-month return on equity of 43.79% and a negative net margin of 228.19%. The business's revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period last year, the company earned ($1.00) EPS.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (9.30%), Price T Rowe Associates Inc. MD (4.45%), JPMorgan Chase & Co. (3.70%), ArrowMark Colorado Holdings LLC (2.25%), T. Rowe Price Investment Management Inc. (2.17%) and American Century Companies Inc. (1.74%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $27.32.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.46 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.32) on an earnings per share basis.

How many employees does Arvinas have?

The company employs 280 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 4/1/2023 by MarketBeat.com Staff